Clinical Trial Update: NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial of NBI-1117568 in inpatient adults with schizophrenia is currently recruiting. The study is sponsored by Neurocrine Biosciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NBI-1117568

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING